Our focus
Leading devices for diagnosis and minimally-invasive treatments of peripheral vascular disease and cancer.
Leading devices for diagnosis and minimally-invasive treatments of peripheral vascular disease and cancer.
Advancing the treatment of arterial disease.
Over 200M patients around the world suffer from Peripheral Arterial Disease (PAD) with less than 1% receiving an intervention. We’ve built a strong portfolio of products to serve this market and are uniquely positioned to provide physicians and hospital systems with a full toolbox of solutions to treat patients.
Venous therapies.
Our venous portfolio offers a category-leading breadth of venous technologies including: venous stents, endovenous chemical ablation, ultrasound assisted clot dissolution devices, mechanical thrombectomy and imaging catheters.
Next-generation interventional oncology & embolization technologies.
With targeted treatments, we can improve the lives of patients suffering from cancer and other life-altering diseases. We offer the largest interventional oncology & embolization portfolio in the industry, which includes Y-90, coils, beads, and cryoablation systems, along with access and delivery devices.
200M+
patients suffer from PAD globally.2
2.5M
cases of DVT annually in the U.S. and Europe.3
850K
diagnosed with liver cancer each year globally.4
2M+
patients suffer from CLI globally.5
PE
causes more US deaths annually than breast cancer & AIDS combined.6
Sources
*In the U.S., TheraSphere is not indicated for metastatic liver cancer treatment